19
PARTICIPATING COUNTRIESa
Here you can find information on the design of NOVELTY and its sub-studies.
NOVELTY is a global, prospective, observational study, which is following ~12,000 patients over 3 years, with selected study sites participating in a 2-year extension study.
NOVELTY study animation
Watch our short animation to learn more about the NOVELTY study, who is eligible to take part and what we hope to achieve
NOVELTY study infographic
Download a PDF of the NOVELTY study infographic
Who are the patients?
- They have a diagnosis, or suspected diagnosis, of asthma and/or COPD, and include those recently diagnosed
- They are ≥12 years of age (≥18 years of age in many countries)
- They have been enrolled from primary care and specialist care settings.a
Where are the patient data coming from?
- Electronic case report forms (eCRFs) specially designed for this study, completed by the physician every year
- Spirometry measurements taken by the physician
- Patient-reported outcome (PRO) questionnaires completed by the patient every 3 months
- Biosamples from consenting patients.a
What is being investigated?
- Patient characteristics, the burden of illness and treatment patterns over time
- How these are influenced by patient factors, e.g., country of residence, demographics, exposures, symptom history, treatment history, concurrent clinical features, treatment setting, socioeconomic setting and access to healthcare
- Biomarkers and clinical parameters associated with differential outcomes, to identify novel phenotypes* and endotypes†a.
Footnotes
*A phenotype is an observable characteristic or trait of a disease, such as morphology, development, biochemical or physiological properties, without necessarily any implication of a mechanism.
†An endotype is a subtype of a condition, defined by a distinct functional or pathobiological mechanism.